About US
Contact us
-
Backlash to Allergan's tribal patent deal builds as House lawmakers launch probeAfter five senators came out against the company's tribal licensing deal and Allergan CEO Brent Saunders took a chance to respond, the drugmaker's patent defense strategy is drawing even more attent2017/9/28
-
Gilead offers its newest HIV drug candidate to patent pool for low-cost productionGilead Sciences is licensing its newest HIV drug candidate, bictegravir,to the U.N.-backed Medicines Patent Pool, meaning it will be produced and sold at a lower cost in 116 low- and middle-income cou2017/9/27
-
Mylan surprises analysts, Teva with long-delayed Copaxone approvalsMylan’s long been frustrated by delays for a pair of high-profile generic products. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense. The FDAgreenlight2017/9/27
-
Allergan moneymaker Botox grabs another cosmetic approval, this time in forehead linesAllergan’s Botox, which the company has called a “pipeline in a drug,” has delivered again.On Tuesday, the FDAapprovedthe blockbuster product to temporarily improve the appearance of certain forehead2017/9/26
-
As Eli Lilly moves some marketing in-house, should ad agencies brace for fallout?Eli Lilly is moving to a new marketing model as part of its corporatepush to manage expenses, but what does that mean for its advertising and marketing agency partners? So far, no one is saying exactl2017/9/26
-
Big Pharma including Pfizer, Sanofi meet to fight noncommunicable diseases around the worldBig pharma is coming together to advance noncommunicable disease care in the developing world. An initiative called Access Acceleratedbrings together more than 20 of the largest pharma companies to ad2017/9/25
-
For Endo's new campaign partner, golf pro Herron, Dupuytren's is all in the familyPGA golf pro Tim Herron has more than passing knowledge of hand deformity Dupuytren’s contracture: He, his father and his sister all have the condition. So he reached out to Endo Pharmaceuticals, make2017/9/25
-
French police visit Merck KGaA offices in inquiry into Levothyrox complaintsFrench police searched the French offices of Merck KGaA as consumer complaints have piled up over a formulation change the drugmaker made to thyroid drug Euthyrox at the request of French regulators.2017/9/22
-
Allergan CEO Saunders defends Restasis deal by calling for review of patent challenge processOne day after Allergan's tribal licensing deal on Restasis drew attention from a powerful senator, the drugmaker sought to further justify its agreement by attacking the patent review system. In a T2017/9/22
-
FDA’s Gottlieb pushes new generics rules to encourage price competitionThe FDA’s role in drug development has always been to green light safe and effective drugs—not to influence how companies price them. But that was before consumers protested price hikes on Mylan’s Epi2017/9/21